UNC Lineberger Comprehensive Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, UNC Lineberger Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count).

366 total trials 79 currently recruiting 209 completed early-phase tilt top decile by trial count

UNC Lineberger Comprehensive Cancer Center: 366 sponsored US clinical trials, 79 recruiting.

UNC Lineberger Comprehensive Cancer Center sponsors 366 registered US clinical trials on ClinicalTrials.gov, 79 of them currently recruiting, and 209 completed. 2 of these trials are in Phase 3-4 (later-stage) and 157 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 29 trials.

Top-decile sponsor footprint

UNC Lineberger Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 52/100

209 of 246 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

366 total, page 4 of 8

COMPLETED

Financial Difficulty in Patients With Blood Cancer

NCT05212233

COMPLETED NA

Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma

NCT04999085

COMPLETED NA

Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings

NCT04931251

COMPLETED NA

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®

NCT05011890

COMPLETED NA

Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study

NCT04978350

COMPLETED NA

Impact of Vaping Prevention Advertisements

NCT04836455

COMPLETED

Transitioning Care: Perspectives of Older Women With Early Breast Cancer on Current Telemedicine Modalities

NCT04990934

COMPLETED NA

Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes

NCT04974489

COMPLETED NA

Mobile Coaching to Improve HPV Vaccine Delivery

NCT05105711

TERMINATED

Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

NCT04920188

COMPLETED

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

NCT04645667

COMPLETED

Chemotherapy-related Cognitive Impairment and Acute Leukemia

NCT04644419

COMPLETED NA

Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)

NCT04492007

COMPLETED Phase 2

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

NCT04021238

COMPLETED NA

An Evaluation of the Families Addressing Cancer Together (FACT) Intervention

NCT04342871

TERMINATED NA

PET/MR Characterization of Renal Cell Carcinomas

NCT04271254

COMPLETED NA

RN-Led Palliative and Supportive Care Intervention

NCT04570709

COMPLETED NA

Clinical Evaluation of Primary Sampling Scatter Correction for Chest Tomosynthesis

NCT04076696

COMPLETED Phase 3

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

NCT04535141

COMPLETED NA

Effect of Incidental Findings Information on Lung Cancer Screening Intent

NCT04432753

TERMINATED Phase 2

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

NCT04176497

COMPLETED NA

Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)

NCT04406714

COMPLETED

Patient-centered Communication About Healthy Weight in Early Breast Cancer

NCT04504201

COMPLETED NA

The HealthScore Health Coaching Program

NCT04923997

COMPLETED NA

Improving Quality of Life After Thoracic Surgery Using Patient-Reported Outcomes

NCT04342260

COMPLETED

LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)

NCT04292847

COMPLETED

Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia

NCT04274465

TERMINATED NA

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

NCT04273724

TERMINATED NA

Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention

NCT04092816

COMPLETED Phase 2

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

NCT04033419

COMPLETED Phase 2

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

NCT03907657

COMPLETED NA

High Intensity Interval Training in Endometrial Cancer

NCT04025229

COMPLETED

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

NCT03885830

COMPLETED NA

The STEPP Study: Sensors To Evaluate Physical Performance

NCT03952767

TERMINATED Early Phase 1

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

NCT03694834

COMPLETED Phase 4

Academic-Industrial Partnership for Translation of Acoustic Angiography

NCT03544268

COMPLETED NA

Testing the Utilization of a Mobile Health App for Patients Undergoing Cystectomy Surgery for Bladder Cancer

NCT03862105

COMPLETED Phase 2

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

NCT03765229

TERMINATED Phase 1

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

NCT03597009

COMPLETED NA

Novel MRI Sequence MR Fingerprinting in Breast MRI Feasibility Study

NCT03846947

TERMINATED NA

PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo

NCT04149353

TERMINATED Early Phase 1

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

NCT03361800

COMPLETED NA

GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses

NCT03819569

COMPLETED NA

Multimedia Aid Gynecologic Counseling and Consent

NCT03899441

COMPLETED NA

MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback

NCT03820024

COMPLETED Phase 2

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

NCT03620019

COMPLETED NA

Promoting Physical Activity in Young Adult Cancer Survivors Using mHealth and Adaptive Tailored Feedback Strategies

NCT03569605

COMPLETED NA

Efficacy of a Couple-Focused mHealth Symptom Self-management Program

NCT03489057

COMPLETED

ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer

NCT03785782

COMPLETED NA

Trial of Parotid Sparing Whole Brain Radiation

NCT03595878

← Previous Page 4 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 71
Phase 2 86
Phase 3 1
Phase 4 1

What is open in the UNC Lineberger Comprehensive Cancer Center pipeline

79 recruiting of 366 indexed (22% open); 209 completed (57%).

Phase mix: 2 late (III/IV) vs 157 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (29 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

UNC Lineberger Comprehensive Cancer Center: open-pipeline peers nationwide

Peers matched on 366 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20%25% Total trials Recruiting share UNC Lineberger Comprehensive Cancer CenterRoswell Park Cancer InstituteUniversity of California, IrvineNew York State Psychiatric InstituteNorthwell HealthWomen and Infants Hospital of Rhode IslandMerck Sharp & DohmeHenry M. Jackson Foundation for the Advancement of Military MedicineAbbVie
UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 366 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

What to do with this UNC Lineberger Comprehensive Cancer Center page

366 registered trials is a research-attention snapshot, not an endorsement of UNC Lineberger Comprehensive Cancer Center or any single study.

  • 79 of UNC Lineberger Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition UNC Lineberger Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

UNC Lineberger Comprehensive Cancer Center pipeline card: 366 registered trials from official public datasets.Report a data error.